Between 1982 and 1985, a single 1500 mg dose of rifampin (RMP) was given to 136 multibacillary leprosy patients who had become clinically inactive and skin-smear negative after various durations of dapsone monotherapy, and then antileprosy chemotherapy was totally stopped. By the end of June 1992, 15 relapses were detected among these patients. The overall relapse rate was 11%; the relapse rate per 100 patient-years was 2.1%, which was the highest among those published to date; the cumulative risk of relapse at year 7 of follow up was 8.8%. All of these figures indicate that the relapse rate among this group was at least the same as in other studies where patients received dapsone monotherapy only. Therefore, the administration of a single large dose of RMP could neither prevent relapse nor reduce its rate among multibacillary patients who had already become clinically and skin-smear negative after dapsone monotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH syndrome) treated with dapsone monotherapy.
Med Clin (Barc)
January 2025
Servicio de Dermatología, Hospital Universitario San Cecilio, Granada, España.
Article Synopsis
- A 47-year-old woman with several autoimmune and metabolic conditions presented with a painful skin rash characterized by raised, yellow-centered plaques on sun-exposed areas.
- A biopsy revealed specific histopathological features that led to a diagnosis of annular elastolytic giant cell granuloma (AEGCG), a rare inflammatory skin disorder potentially triggered by sunlight exposure.
- The patient showed significant improvement after being treated with ciclosporin, alleviating symptoms like itching and pain, highlighting the challenges in managing AEGCG, which is often resistant to standard treatments.
Clinical and laboratory findings characterizing the need for systemic corticosteroids and nonsteroidal systemic therapies and the predicted outcomes in cutaneous polyarteritis nodosa: a single-centre retrospective analysis.
Clin Exp Dermatol
October 2024
Department of Dermatology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Article Synopsis
- cPN is a rare skin condition affecting medium-sized blood vessels, with no standard treatment or predictors of disease severity.
- Researchers studied 36 patients to identify which clinical signs could indicate a need for systemic corticosteroid therapy to control their condition.
- Results showed that while over half of the patients achieved remission without corticosteroids, elevated white blood cell counts, high erythrocyte sedimentation rates, and skin ulcers were indicators of those who might require steroids for treatment.
Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.
Front Microbiol
November 2023
Division of Immunology, Tulane National Primate Research Center, Tulane University, Covington, LA, United States.
Lyme disease (LD) results from the most prevalent tick-borne infection in North America, with over 476,000 estimated cases annually. The disease is caused by which transmits through the bite of Ixodid ticks. Most cases treated soon after infection are resolved by a short course of oral antibiotics.
View Article and Find Full Text PDFHypocomplementemic Urticarial Vasculitis Associated With Hashimoto's Thyroiditis and Hepatitis B Virus Infection: A Case Report.
Cureus
September 2022
Department of Dermatology I, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Urticarial vasculitis (UV) is an uncommon condition characterized by recurrent episodes of urticarial lesions and angioedema and the pathological features of leukocytoclastic vasculitis. UV divides into two subgroups based on the level of serum complement. Usually, patients with hypocomplementemia experience internal organ involvement and an unfavorable prognosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!